TRAW Traws Pharma Inc: Accounting Value per Share

Graphic logo of Traws Pharma (TRAW)

Traws Pharma, Inc. (TRAW) generates revenue through government procurement and licensing for respiratory infection therapies. Book value data demonstrates stability, with 0.11 representing the most recent metric reading. Financial stability is underpinned by adherence to bioethics and ESG waste disposal standards, as well as the successful completion of rigorous FDA toxicity audits for drugs during clinical trials.

Traws Therapeutics (TRAW): Share Book Value from 04/04/2024 to 10/28/2026

Traws Pharma Inc - analytical breakdowns and key metrics (TRAW)

- price and consensus price forecast:
Stock Price Traws Therapeutics|TRAW - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Traws Pharma, Inc.|TRAW - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Traws Pharma|TRAW - Net Asset Value|Market Capitalization to Book Value Ratio trawspharma.com|TRAW - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Traws Pharma, Inc.|TRAW - Long-Term Debt to Capital|Short-Term Debt to Equity Traws Therapeutics|TRAW - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Traws Pharma, Inc.
Fundamental company valuation:trawspharma.com - TRAW
Manufactured products of Traws Therapeutics

The efficiency of Traws Pharma, Inc. (TRAW) diversified logistics corridors is reflected in the historical book value per share, which confirms the preservation of the company's tangible resources. According to US GAAP, this metric is defined as the difference between assets and liabilities divided by the number of shares, allowing investors to assess the real value of their ownership stake excluding market speculation and overinflated expectations.

Competitors of Traws Pharma, Inc. (TRAW)

Gilead Sciences Inc - Book Value per Share|Cidara Therapeutics Corp (CDTX) - Book Value per Share|NVAX (Novavax, Inc.) - Accounting Value per Share|CVAC (curevac.com) - Accounting Value per Share|Net Assets per Single Share Valneva VALN|Share Book Value Vir Biotechnology Inc|SIGA Corp (SIGA) - Book Value per Share|Accounting Value of a Share Emergent Bio (EBS)|Book Value per Share AVIR (Atea Pharmaceuticals)|Invivyd Inc - Book Value per Share|Net Assets per Single Share Enanta Pharmaceuticals, Inc. (ENTA)|INO: Accounting Value of a Share|HLVX (HilleVax Corp) - Net Assets per Single Share|Kalaris Tx (KLRS) - Accounting Value per Share|DYAI (Dyadic International Inc) - Book Value per Share|Book Value per Share NanoViricides Corp (NNVC)|Talphera (TLPH) - Accounting Value per Share|Accounting Value of a Share Cocrystal Pharma Inc COCP|Accounting Value per Share Dogwood Therapeutics DWTX|Net Assets per Single Share Qualigen Corp QLGN|Book Value per Share ALVR (AlloVir Bio)|VBIV: Net Assets per Share|Net Assets per Single Share virios.com VIRI|Accounting Value of a Share Vaxart